XpertDox launches XpertTrial, a search engine for finding ongoing clinical trials for over 6,000 diseases
By: XpertDox LLC
BIRMINGHAM, Ala. - Nov. 29, 2017 - PRLog -- XpertDox has launched the new Clinical Trial finder search engine. This functionality will enable the patients to find all ongoing clinical trials for a particular disease.
The new clinical trial finder functionality has significant improvements over the existing options. The existing products use a direct mapping method for finding the ongoing clinical trials for a disease. This approach has a significant drawback as it misses out on finding search results for closely related diseases. XpertDox's clinical trial algorithm has leveraged big data analyses to create network mapping and has been able to address the shortcomings in its XpertTrial offering.
XpertTrial is a natural language processing search engine with 50,000 keywords for all diseases, procedures, symptoms, and specialties matched to a list of active trials in the hospital. The clinical trial finder tool, XpertTrial, is an addition to the already existing suite of products that are geared to improve patient access. XpertMatch suite of products which were launched previously maps 7,000 disease, procedures and symptoms to a million doctors and 4,500 hospitals in the US.
XpertDox is a website focused exclusively on improving patient access. They have built a database of 130 specialties, 6,000 diseases and 200 procedures. Powered by their proprietary algorithm, XpertDox evaluates all doctors and hospitals in the U.S. in the five critical domains of clinical expertise, research, educational contributions, leadership role among peers and recognition as an expert.
XpertDox offers its doctor finder and clinical trial finder tool to other organizations such as hospitals, medical group practices, and insurance companies that want to improve their search engine for doctors and ongoing clinical trials. XpertDox is also facilitating pharmaceutical companies and clinical research organizations to accelerate the enrollment of patients with rare diseases for clinical trials.